Pacira BioSciences, Inc.
Pacira BioSciences, Inc. (PCRX) Stock Ownership
Institutional vs insider vs public ownership from 13F and float data — top holders, activity, and insider trades below.
SEC 13F · FMP · PCRX · as of Mar 31, 2025
Ownership Breakdown
244
Institutional Holders
▼ 2 vs Q4
$1.26B
Total Inst. Value
▲ $316.70M vs Q4
39.34M
Shares Outstanding
freeFloat 95.94%
50.63M
13F Shares Held
▲ 658,417 vs Q4
Institutional ownership = 13F shares ÷ total outstanding. Insider % = 100 − free float. Public % = free float − institution %. Data: FMP /symbol-positions-summary + /shares-float + SEC EDGAR.
Top Institutional Holders
PCRX largest shareholders · institutional ownership
Q1 2025 · SEC 13F
Showing top 10 holders
| Holder | Shares | % Owned | Weight | Value | Reported | Change |
|---|---|---|---|---|---|---|
BLACKROCK, INC. pharmaceutical preparations | 7.65M | 16.54% | 16.54% | $190.19B | May 2, 2025 | ▼ 56.5K |
VANGUARD GROUP INC pharmaceutical preparations | 5.24M | 11.33% | 11.33% | $130.26B | May 9, 2025 | ▼ 22.1K |
D. E. SHAW & CO., INC. pharmaceutical preparations | 2.26M | 4.89% | 4.89% | $56.26B | May 15, 2025 | ▲ 6.4K |
RENAISSANCE TECHNOLOGIES LLC pharmaceutical preparations | 2.24M | 4.84% | 4.84% | $55.68B | May 14, 2025 | ▲ 248.0K |
DIMENSIONAL FUND ADVISORS LP pharmaceutical preparations | 2.05M | 4.43% | 4.43% | $50.93B | May 13, 2025 | ▲ 217.2K |
STATE STREET CORP pharmaceutical preparations | 1.98M | 4.28% | 4.28% | $49.19B | May 15, 2025 | ▲ 13.9K |
DOMA PERPETUAL CAPITAL MANAGEMENT LLC pharmaceutical preparations | 1.80M | 3.90% | 3.90% | $44.83B | May 15, 2025 | ▲ 56.2K |
BALYASNY ASSET MANAGEMENT L.P. pharmaceutical preparations | 1.57M | 3.38% | 3.38% | $38.90B | May 15, 2025 | ▲ 1.13M |
CITADEL ADVISORS LLC pharmaceutical preparations | 1.33M | 2.87% | 2.87% | $33.05B | May 15, 2025 | ▲ 1.28M |
ALYESKA INVESTMENT GROUP, L.P. pharmaceutical preparations | 1.31M | 2.83% | 2.83% | $32.51B | May 15, 2025 | NEW |
Data from SEC Form 13F filings. Ownership bar normalised to largest holder. Change flags: isNew / isSoldOut / changeInSharesNumber (FMP extract-analytics/holder).
Institutional Activity
Q1 2025 vs prior quarter
Q1 2025
29
Increased
+7.19M shares2
New Positions
first time holders18
Decreased
−5.35M shares0
Sold Out
fully exitedNet shares change (top 50)
+1.85M
+7.19M / −5.35M
Net new holders
+13
2 new / 0 exited
Based on top 50 institutional holders by position size. Fields: isNew, isSoldOut, changeInSharesNumber (FMP extract-analytics/holder, limit=50).
Insider Buying vs Selling
PCRX insider trading · insider activity
Source: SEC Form 4
Insiders have been primarily selling shares recently. Selling may be driven by pre-scheduled Rule 10b5-1 plans rather than negative sentiment.
4
Buy transactions
11
Sell transactions
0.36
Buy/Sell ratio
$0M
Total disposed
Recent Insider Transactions
Showing 10 most recent · Common Stock only
| Name · Role | Date | Type | Shares | Price | Value | After Trans. | Filing |
|---|---|---|---|---|---|---|---|
RIKER LAUREN Senior Vice President, Finance | Jun 3, 2026 | Tax Withhold | 3,187 | $22.32 | $71.1K | 68.4K | Form 4 ↗ |
SLONIN JONATHAN Chief Medical Officer | Jun 3, 2026 | Tax Withhold | 4,728 | $22.32 | $105.5K | 218.9K | Form 4 ↗ |
WILLIAMS KRISTEN Chief Administrative Officer | Jun 3, 2026 | Tax Withhold | 8,528 | $22.32 | $190.3K | 177.3K | Form 4 ↗ |
WILLIAMS KRISTEN Chief Administrative Officer | Jun 4, 2026 | Sale | 10,259 | $22.27 | $228.5K | 167.1K | Form 4 ↗ |
Cross Shawn Chief Financial Officer | Apr 23, 2026 | Sale | 12,941 | $25.16 | $325.6K | 105.3K | Form 4 ↗ |
Cross Shawn Chief Financial Officer | Apr 20, 2026 | Sale | 7,714 | $25.14 | $193.9K | 105.3K | Form 4 ↗ |
Cross Shawn Chief Financial Officer | Apr 22, 2026 | Sale | 1,500 | $25.01 | $37.5K | 105.3K | Form 4 ↗ |
Kronenfeld Mark A. director | Jun 11, 2025 | Award | 6,163 | — | — | 31.1K | Form 4 ↗ |
SLONIN JONATHAN Chief Medical Officer | Mar 17, 2026 | Sale | 3,261 | $22.82 | $74.4K | 223.6K | Form 4 ↗ |
Froimson Mark director | Mar 17, 2026 | Sale | 500 | $21.81 | $10.9K | 20.1K | Form 4 ↗ |
Source: /insider-trading/search (FMP stable). Buy/Sell direction: acquisitionOrDisposition A=Buy, D=Sell. RSU vesting (M-Exempt) excluded from sentiment bar. All data from SEC EDGAR public filings.
About institutional & insider ownership
Pacira BioSciences, Inc. (PCRX) is primarily owned by institutional investors, who hold approximately 100.0% of total shares outstanding. Company insiders own approximately 4.06%, while retail and public investors account for the remaining 0.00%.
The largest institutional shareholder of Pacira BioSciences, Inc. is BLACKROCK, INC., holding approximately 7.65 million shares — equal to 16.54% of outstanding shares — as of March 31, 2025.
A total of 244 institutional investors currently hold PCRX stock, with a combined institutional value of approximately $1.26 billion as of the most recent 13F filing period.
Frequently asked questions
PCRX ownershipPacira BioSciences, Inc. (PCRX) is primarily owned by institutional investors, who hold approximately 100.0% of shares. The largest shareholder is BLACKROCK, INC. with a 16.54% stake. Company insiders hold 4.06%. Data sourced from SEC Form 13F as of March 31, 2025.